Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea

Virology Journal

Ju-yeon Choi¹  Hye-Ri Oh¹  Mina Park¹  Mee-Kyung Kee¹  Jee Eun Rhee¹  Sung Soon Kim¹  Oh-Kyung Kwon¹ 

[1] Department of Immunology and Pathology, Division of AIDS, Korea National Institute of Health, Osong, Republic of Korea

关键词: Korea;    Treatment-experienced;    Darunavir;    Etravirine;    Genotypic drug resistance;    Phenotypic drug susceptibility;   

Others  :  1225288
DOI  :  10.1186/s12985-015-0283-7

 received in 2014-09-29, accepted in 2015-03-19,  发布年份 2015

【 摘 要 】

Background

In South Korea, about 20 types of antiretroviral drugs are used in the treatment of patients with human immunodeficiency virus/acquired immune deficiency syndrome. Since 2010, raltegravir, etravirine, and darunavir have been spotlighted as new drugs for highly active antiretroviral therapy (HAART)-experienced adults with resistant HIV-1 in South Korea. In this study, we investigated potential susceptibility of pseudoviruses derived from treatment-experienced Korean patients to etravirine vs efavirenz and to darunavir vs amprenavir and indinavir using a modified single-round assay.

Methods

Pseudoviruses derived from nine treatment-experienced patients infected with HIV-1 were investigated by comparison with the wild-type strain pNL4-3. The 50% inhibitory concentration (IC₅₀) values were calculated and drug susceptibility was compared. The intensity of genotypic drug resistance was classified based on the ‘SIR’ interpretation of the Stanford data base.

Results

Drug susceptibility was generally higher for etravirine and darunavir compared with efavirenz, amprenavir, and indinavir in pseudoviruses derived from treatment-experienced patients. Pseudoviruses derived from patients KRB4025 and KRB8014, who exhibited long-term use of protease inhibitors, showed an outside of tested drug concentration, especially for amprenavir and indinavir. However, they exhibited a lower fold-change in resistance to darunavir.

Conclusions

Etravirine and darunavir have been used in HAART since 2010 in South Korea. Therefore, these antiretroviral drugs together with other newly introduced antiretroviral drugs are interesting for the optimal treatment of patients with treatment failure. This study may help to find a more effective HAART in the case of HIV-1 infected patients that have difficulty being treated.

【 授权许可】

   
2015 Kwon et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Antiretroviral drugs used in the treatment of HIV infection. US Food and Drug Administration. http://www.fda.gov/forpatients/illness/hivaids/treatment/ucm118915.htm.
• [2]Tang MW, Shafer RW. HIV-1 antiretroviral resistance scientific principles and clinical applications. Drugs. 2012; 72(9):e1-25.
• [3]Sung H, Foley BT, Bae IG, Chi HS, Cho YK. Phylogenetic analysis of reverse transcriptase in antiretroviral drug-naïve Korean HIV type 1 patients. AIDS Res Hum Retroviruses. 2001; 17(16):1549-54.
• [4]Sung H, Foley BT, Ahn SH, Kim YB, Chae JD, Shin YO et al.. Natural polymorphisms of protease in protease inhibitor-naive HIV-1 infected patients in Korea: a novel L63M in subtype B. AIDS Res Hum Retroviruses. 2003; 19(6):525-30.
• [5]Paredes R, Clotet B. Clinical management of HIV-1 resistance. Antiviral Res. 2010; 85:245-65.
• [6]Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW et al.. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013; 21(1):6-14.
• [7]Melikian GL, Rhee SY, Varghese V, Porter D, White K, Taylor J et al.. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014; 69(1):12-20.
• [8]Elsayed RK, Caldwell DJ. Etravirine: a novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection. Am J Health Syst Pharm. 2010; 67:193-205.
• [9]Towner WJ, Cassetti I, Domingo P, Nijs S, Kakuda TN, Vingerhoets J et al.. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther. 2010; 15:803-16.
• [10]Sterrantino G, Zaccarelli M, Colao G, Baldanti F, Di Giambenedetto S, Carli T et al.. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis. Infection. 2012; 40:311-8.
• [11]Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H et al.. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother. 2010; 54(6):2473-9.
• [12]de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res. 2010; 85:75-90.
• [13]Peeters M, Vingerhoets J, Tambuyzer L, Azijn H, Hill A, De Meyer S et al.. Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials. AIDS. 2010; 24:921-30.
• [14]Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 2010; 85:59-74.
• [15]Dierynck I, De Meyer S, Lathouwers E, Vanden Abeele C, Van De Casteele T, Spinosa-Guzman S et al.. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naïve patients. Antivir Ther. 2010; 15:1161-9.
• [16]Barrail-Tran A, Yazdanpanah Y, Goldwirt L, Chene G, Colin C, Piketty C et al.. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment-experienced patients. AIDS. 2010; 24(16):2581-3.
• [17]Xu HT, Oliveira M, Asahchop EL, McCallum M, Quashie PK, Han Y et al.. Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase. J Virol. 2012; 86(23):12983-90.
• [18]Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J et al.. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol. 2004; 78(4):1718-29.
• [19]Choi JY, Kwon OK, Choi SY, Park YK, Kim SS. Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay. J Clin Virol. 2011; 50:19-25.